Chemomab Therapeutics Ltd. (CMMB) › Operating Cash FlowChemomab Therapeutics Ltd. (CMMB) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2018: -$14.22M2019: -$16.46M2020: -$5.24M2021: -$12.37M2022: -$20.37M2023: -$23.61M2024: -$15.39M2025: -$11.13M-$11.13M2018Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$11.13M+27.7%2024-$15.39M+34.8%2023-$23.61M-15.9%2022-$20.37M-64.6%2021-$12.37M-136.1%2020-$5.24M+68.1%2019-$16.46M-15.7%2018-$14.22M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share